Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Bellus Health Soars After Results in Trial of Chronic Cough Treatment

Published 2021-12-13, 10:38 a/m
Updated 2021-12-13, 10:38 a/m
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing.com – BELLUS Health Inc. (TSX:BLU) stock surged 64% Monday after the company revealed positive results from a trial of a treatment it is developing against refractory chronic cough.

RCC is a cough lasting more than eight weeks despite appropriate treatment. Around 9 million patients in the U.S. are estimated to be suffering from RCC.

The company expects to meet the Food and Drug Administration between April and June and begin a phase-3 study of the treatment in the second half of the year.

The stock touched a high of $9.39 so far on Monday.

Bellus is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders.

The company reported its third-quarter numbers last month, reporting losses that more than tripled to $23 million. Research and development expenses rose 229%, to $19 million.

Currently, there is no specific therapy approved for RCC and treatment options are limited, according to Bellus. The trial enrolled 249 participants with a baseline awake cough frequency of 25 per hour and more.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.